日付	始値	高値	安値	終値	前日比	出来高	時価総額	25日乖離
2026
10/23	3,097	3,097	3,026	3,036	+0.26%	2,751,900	-	+5.42%
10/22	3,017	3,049	3,001	3,028	+0.23%	2,438,300	-	+5.43%
10/21	3,020	3,050	2,996	3,021	+1.41%	3,443,800	-	+5.48%
10/20	2,939	2,979	2,927	2,979	+1.36%	1,777,500	-	+4.27%
10/19	2,963	2,975	2,919	2,939	+0.17%	2,071,200	-	+3.05%
10/16	2,895	2,948	2,886	2,934	+1.35%	2,844,400	-	+2.95%
10/15	2,817	2,896	2,800	2,895	+3.76%	6,215,800	-	+1.58%
10/14	2,791	2,800	2,762	2,790	-0.89%	2,263,900	-	-2.14%
10/13	2,783	2,818	2,756	2,815	+2.55%	2,908,200	-	-1.54%
10/09	2,758	2,778	2,734	2,745	-0.87%	3,305,800	-	-4.22%
10/08	2,800	2,804	2,728	2,769	+0.22%	3,365,500	-	-3.65%
10/07	2,724	2,779	2,711	2,763	0%	3,910,100	-	-4.03%
10/06	2,694	2,763	2,687	2,763	+3.83%	4,590,400	-	-4.23%
10/05	（IR情報）15:00 米国IntraBio社の完全子会社化に関するお知らせ
10/05	2,768	2,784	2,649	2,661	-4.49%	6,383,300	-	-7.96%
10/02	2,813	2,832	2,766	2,786	-2.31%	3,322,400	-	-4%
10/01	2,850	2,878	2,805	2,852	-0.66%	2,743,400	-	-1.89%
09/30	2,827	2,883	2,808	2,871	+1.13%	3,565,700	-	-1.34%
09/29	2,877	2,885	2,822	2,839	-2.71%	2,838,900	-	-2.51%
09/28	2,924	2,956	2,915	2,918	-0.68%	3,096,000	-	+0.1%
09/25	2,940	2,963	2,929	2,938	+0.69%	2,423,900	-	+0.86%
09/24	2,945	2,958	2,915	2,918	-1.25%	3,084,900	-	+0.31%
09/18	2,971	2,985	2,947	2,955	-0.94%	3,861,900	-	+1.76%
09/17	2,917	2,988	2,902	2,983	+3.15%	2,058,600	-	+2.9%
09/16	（IR情報）15:00 「ブイタマークリーム」の国内における小児(12歳未満)アトピー性皮膚炎に対する用法・用量追加の製造販売承認取得について
09/16	（IR情報）15:00 組み換えタンパクワクチン「コブゴーズ筋注」の国内における一部変更承認の取得について
09/16	2,888	2,918	2,871	2,892	-0.41%	2,366,600	-	-0.03%
09/15	2,914	2,948	2,900	2,904	+1.75%	2,690,100	-	+0.48%
09/14	2,840	2,862	2,818	2,854	+0.96%	1,950,100	-	-1.14%
09/11	2,819	2,834	2,791	2,827	-0.14%	3,364,400	-	-2.04%
09/10	2,832	2,847	2,808	2,831	-0.56%	2,442,700	-	-1.91%
09/09	2,885	2,892	2,846	2,847	-1.76%	2,897,500	-	-1.25%
09/08	2,923	2,926	2,888	2,898	-1.53%	2,177,900	-	+0.63%
09/07	2,942	3,005	2,928	2,943	+1.17%	3,526,800	-	+2.19%
09/04	2,946	2,968	2,904	2,909	-2.77%	3,499,800	-	+1.08%
09/03	2,980	3,026	2,968	2,992	+0.34%	2,843,600	-	+3.74%
09/02	2,963	3,005	2,939	2,982	+1.08%	3,320,400	-	+3.29%
09/01	2,909	2,963	2,907	2,950	+1.34%	2,264,800	-	+2.29%
08/31	2,880	2,918	2,871	2,911	-0.07%	3,008,500	-	+1.04%
08/28	2,891	2,927	2,891	2,913	+0.1%	1,463,300	-	+1.18%
08/27	2,906	2,934	2,886	2,910	-0.48%	1,519,200	-	+1.15%
08/26	2,932	2,965	2,908	2,924	+0.45%	1,772,900	-	+1.7%
08/25	2,940	2,960	2,911	2,911	-0.38%	1,506,900	-	+1.29%
08/24	2,920	2,961	2,912	2,922	+0.1%	1,550,400	-	+1.71%
08/21	2,932	2,951	2,912	2,919	-0.48%	2,335,100	-	+1.71%
08/20	2,905	2,945	2,897	2,933	+2.59%	2,628,000	-	+2.3%
08/19	2,881	2,881	2,819	2,859	+0.99%	2,447,000	-	-0.14%
08/18	2,800	2,842	2,789	2,831	+1%	2,106,300	-	-1.08%
08/17	2,851	2,851	2,791	2,803	-1.02%	1,669,800	-	-2.06%
08/14	2,848	2,851	2,810	2,832	+0.46%	2,184,400	-	-1.08%
08/13	2,837	2,848	2,793	2,819	-0.07%	3,351,900	-	-1.61%
08/12	2,797	2,834	2,786	2,821	-0.74%	3,478,600	-	-1.64%
08/10	2,822	2,863	2,803	2,842	+1.14%	2,967,300	-	-1.04%
08/07	2,818	2,858	2,794	2,810	-0.57%	3,710,900	-	-2.19%
08/06	2,750	2,833	2,732	2,826	+2.47%	3,006,000	-	-1.6%
08/05	2,773	2,814	2,739	2,758	-0.61%	3,148,200	-	-3.87%
08/04	2,853	2,900	2,772	2,775	-4.28%	4,060,600	-	-3.31%
08/03	（IR情報）15:30 2026年度第1四半期決算およびHIV事業に関するアップデート説明資料
08/03	（IR情報）15:30 2027年3月期第1四半期決算補足資料
08/03	（IR情報）15:30 2027年3月期第1四半期決算短信〔IFRS〕(連結)
08/03	2,917	2,920	2,825	2,899	-0.34%	2,659,500	-	+0.98%
07/31	2,921	2,951	2,893	2,909	-4.34%	3,058,800	-	+1.54%
07/30	3,050	3,082	2,999	3,041	-0.94%	3,118,900	-	+6.4%
07/29	2,948	3,070	2,920	3,070	+5.75%	3,912,900	-	+7.76%
07/28	2,909	2,930	2,880	2,903	+0.28%	2,128,300	-	+2.25%
07/27	2,855	2,904	2,854	2,895	+1.37%	1,957,400	-	+2.12%
07/24	2,846	2,876	2,826	2,856	+0.28%	1,900,200	-	+0.88%
07/23	（IR情報）15:30 譲渡制限付株式報酬としての自己株式の処分の払込完了について
07/23	2,877	2,885	2,824	2,848	-0.97%	1,989,600	-	+0.64%
07/22	2,876	2,887	2,842	2,876	-0.83%	2,151,500	-	+1.66%
07/21	2,919	2,926	2,870	2,900	+0.83%	3,007,500	-	+2.62%
07/17	2,858	2,929	2,849	2,876	+1.16%	3,508,400	-	+1.91%
07/16	2,848	2,872	2,831	2,843	+0.07%	2,218,900	-	+0.89%
07/15	2,915	2,915	2,810	2,841	-0.28%	2,431,300	-	+0.92%
07/14	2,832	2,874	2,820	2,849	+1.1%	2,084,600	-	+1.28%
07/13	2,837	2,837	2,806	2,818	-0.53%	2,070,600	-	+0.28%
07/10	2,865	2,865	2,803	2,833	-0.07%	2,194,800	-	+0.78%
07/09	2,872	2,893	2,814	2,835	-1.36%	2,418,600	-	+0.82%
07/08	2,955	2,959	2,861	2,874	-1.2%	3,303,000	-	+2.2%
07/07	2,926	2,958	2,899	2,909	-0.48%	2,914,200	-	+3.52%
07/06	2,892	2,930	2,871	2,923	+1.88%	1,916,700	-	+4.17%
07/03	2,889	2,941	2,851	2,869	+3.09%	2,854,600	-	+2.32%
07/02	2,776	2,805	2,731	2,783	+1.87%	2,776,300	-	-0.93%
07/01	2,689	2,789	2,688	2,732	-2.04%	2,703,500	-	-3.05%
06/30	2,813	2,817	2,764	2,789	-0.61%	3,453,700	-	-1.45%
06/29	2,770	2,835	2,767	2,806	+1.85%	2,918,500	-	-1.13%
06/26	2,740	2,767	2,716	2,755	+1.32%	2,409,300	-	-3.23%
06/25	2,800	2,808	2,719	2,719	-3.62%	2,915,300	-	-4.76%
06/24	（IR情報）17:00 譲渡制限付株式報酬としての自己株式の処分について
06/24	（IR情報）16:00 資本コストや株価を意識した経営の実現に向けた対応に関するお知らせ
06/24	2,810	2,837	2,785	2,821	+0.04%	2,475,200	-	-1.57%
06/23	2,838	2,850	2,800	2,820	+0.28%	2,447,600	-	-1.88%
06/22	2,780	2,812	2,771	2,812	+1.15%	1,742,600	-	-2.43%
06/19	（IR情報）14:00 抗新型コロナウイルス(SARS-CoV-2)薬ゾコーバの国内における小児用法・用量の追加承認について
06/19	2,783	2,822	2,760	2,780	-1.87%	3,411,000	-	-3.87%
06/18	（IR情報）13:00 新規抗真菌薬オロロフィムのグローバル第3相臨床試験(OASIS試験)における良好な結果について(速報)
06/18	2,855	2,866	2,820	2,833	0%	2,117,600	-	-2.44%
06/17	2,812	2,846	2,797	2,833	+0.85%	1,868,500	-	-2.78%
06/16	2,870	2,870	2,781	2,809	+0.79%	2,044,800	-	-3.77%
06/15	2,770	2,819	2,770	2,787	+0.4%	1,842,400	-	-5.01%
06/12	2,790	2,805	2,746	2,776	+0.22%	3,282,900	-	-5.93%
06/11	2,671	2,781	2,671	2,770	-1%	2,555,400	-	-6.64%
06/10	2,767	2,798	2,748	2,798	+1.08%	2,614,300	-	-6.17%
06/09	2,840	2,843	2,764	2,768	-2.71%	3,203,900	-	-7.58%
06/08	2,899	2,900	2,822	2,845	-0.7%	2,825,500	-	-5.51%
06/05	2,856	2,894	2,847	2,865	+1.34%	2,584,900	-	-5.29%
06/04	2,858	2,865	2,819	2,827	+0.35%	2,414,500	-	-6.79%
06/03	2,781	2,845	2,767	2,817	-0.21%	2,832,700	-	-7.46%
06/02	2,665	2,850	2,665	2,823	-1.47%	4,575,400	-	-7.62%
06/01	3,003	3,050	2,835	2,865	-4.5%	3,681,400	-	-6.56%
06/01	（IR情報）9:00 抗新型コロナウイルス(SARS-CoV-2)薬エンシトレルビルフマル酸のCOVID-19曝露後発症予防における米国FDAの承認について
05/29	（IR情報）15:00 オピオイド誘発性便秘症治療薬ナルデメジンの中国における新薬承認取得について
05/29	3,000	3,040	2,993	3,000	+0.1%	8,183,800	-	-2.5%

塩野義製薬（4507）のイベントチャート

2026/05/29～2026/10/23

イベント情報＆株価推移

開示資料

決算

株式

チャート